TC
TRVI icon

Tejara Capital’s Trevi Therapeutics TRVI Stock Holding History

Tejara Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,200
Closed -$340K – 73
2025
Q3 		$340K Sell
37,200
-289,195
-89% -$2.17M 0.18% 45
2025
Q2 		$1.79M Buy
326,395
+146,879
+82% +$914K 0.83% 38
2025
Q1 		$1.13M Buy
179,516
+25,777
+17% +$123K 0.44% 54
2024
Q4 		$633K Sell
153,739
-87,874
-36% -$281K 0.41% 43
2024
Q3 		$807K Sell
241,613
-164,375
-40% -$489K 0.38% 47
2024
Q2 		$1.21M Buy
405,988
+368,507
+983% +$1.02M 0.44% 49
2024
Q1 		$129K Sell
37,481
-1,231,519
-97% -$2.75M 0.05% 73
2023
Q4 		$1.7M Buy
1,269,000
+1,088,773
+604% +$1.65M 0.71% 37
2023
Q3 		$393K Hold
180,227
– – 0.22% 54
2023
Q2 		$431K Sell
180,227
-9,991
-5% -$25.2K 0.21% 60
2023
Q1 		$352K Buy
190,218
+40,260
+27% +$91.1K 0.18% 66
2022
Q4 		$289K Buy
+149,958
New +$296K 0.17% 81

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Tejara Capital's TRVI Position: Q4 2025 in Review

Tejara Capital sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 37,200 shares — an estimated $340K sold.

Tejara Capital first reported a position in TRVI in Q4 2022 and held it in 12 quarters. The position peaked at $1.79M in Q2 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • Tejara Capital reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tejara Capital sold 37,200 Trevi Therapeutics shares in Q4 2025, an estimated $340K.
  • Tejara Capital first reported a position in Trevi Therapeutics in Q4 2022 and held it in 12 quarters.
  • Tejara Capital's Trevi Therapeutics position peaked at $1.79M in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on Tejara Capital's 13F filing for Q4 2025, filed 5 Feb 2026.